Abstract The study aimed to determine and compare cadmium (Cd) concentration in different biological media of breast cancer and benign breast tumor patients. Concentration of Cd was determined in breast tissue, urine, and blood of 57 breast cancer and 51 benign tumor patients. Two samples of breast tissue from each patient, i.e., tumor and healthy tissue were taken for the analysis. Cd in biological media was determined by atomic absorption spectrometry (Perkin-Elmer, Zeeman 3030). The mean Cd concentration in breast cancer patients was 0.053 lg/g (95% confidence intervals, CI 0.042-0.065) for tumor sample and 0.02 lg/g (95% CI 0.014-0.026) for healthy breast tissue sample (P \ 0.001). In benign tumor patients, the figures were as follows: 0.037 lg/g (95% CI 0.023-0.051) and 0.032 lg/g (95% CI 0.018-0.047) (P [ 0.05). Cd content in malignant tumor significantly differed from that in benign tumor (P \ 0.01). Cancer patients with positive estrogen receptors (ERs) had significantly greater concentration of breast tissue Cd compared to patients with negative ERs (P = 0.035). Adjusted for creatinine, Cd in urine was significantly higher in cancer patients than in controls (P \ 0.001). In cancer patients, a positive Spearman's correlation was found between Cd in tumor and healthy breast tissue, blood (r = 0.44 and r = 0.39, respectively, P \ 0.01). Correlation between Cd in urine of cancer patients and number of cigarettes smoked during lifetime was suggestive (r = 0.59, P = 0.075). The data obtained show higher concentration of cadmium in breast tumor and urine of cancer patients and support a possible relationship between cadmium and breast cancer.
Introduction
Cadmium (Cd) is a toxic, nonessential, and bioaccumulating heavy metal widely used in industry. Since Cd is highly persistent in the environment, it affects human health both through occupational and environmental exposures. Cd exerts multiple toxic effects, and has been classified as a human carcinogen by the International Agency for Research on Cancer [1] . Cd cancerogenesis can be explained by several mechanisms: (1) aberrant gene expression, (2) inhibition of DNA damage repair, (3) induction of oxidative stress, and (4) inhibition of apoptosis. The most important among them is oxidative stress because of its involvement in Cd-induced aberrant gene expression, inhibition of DNA damage repair, and apoptosis [2] .
Although Cd is known as a human lung carcinogen [1] , there is evidence that it may be related to other cancers such as human prostate cancer [3] [4] [5] , renal cell carcinoma [6, 7] , and breast cancer [8, 9] . The human mammary gland is a controversial target site for Cd. Epidemiological study revealed twice the higher risk of breast cancer in women with creatinine-adjusted urine Cd more than 0.58 lg/g compare to those with Cd less than 0.26 lg/g [9] .
Experimental studies suggest several pathways to explain association of Cd with human breast cancer [8, 10, 11] . There is evidence that Cd may have estrogenicity [8, 12, 13] . According to some authors, the bivalent metal cations Cd belongs to a new class of potent environmental estrogens, referred to as metalloestrogens. The studies in vivo and in vitro show that Cd acts like an estradiol activating estrogen receptor (ER) a through a high-affinity interaction with the hormone binding domain of the receptor [14, 15] . There is evidence that the effects of cadmium are mediated by the ER independent of estradiol [8] .
In order to determine, whether Cd is an etiological factor of breast cancer, measurement of Cd level in vivo is very helpful. Antila et al. [16] defined high content of Cd (3.2-86.9 lg/g) in breast samples from breast cancer patients, but the mean cadmium level did not differ from that of healthy controls. However, two other studies found significant difference between Cd in breast cancer and healthy breast tissue [17, 18] . Until now, there have been no studies investigating Cd levels in different biological media (breast cancer and healthy breast tissue, urine, and blood) among women with breast cancer. This study determined and compared Cd concentration in different biological media of breast cancer and benign breast tumor patients.
Materials and methods

Study population
Our study included 57 newly diagnosed breast cancer patients and 51 patients with benign breast tumor, who required surgical intervention at the Department of Surgery, Kaunas University of Medicine and agreed to participate in the survey.
Breast cancer and benign tumor diagnoses were histologically confirmed (C50 and D05 for breast cancer and D24 for benign tumor according to ICD10). The study was approved by the Kaunas Regional Biomedical Research Ethics Committee (01- No. BE-2-1, Report No. 5/2007). Written consent to fulfill the questionnaire and collect biological media (breast tissue, urine, and blood) specimens was received from each patient.
Questionnaire
The questionnaires were administered at baseline and completed by the patients. The questionnaire was used to collect information on demographic characteristics and smoking.
The samples collection and preparation According to clinical situation, mastectomy or lumpectomy with at least 2 cm free burden from the palpable cancer mass was performed at the Department of Surgery. For each patient two specimens of breast tissue, about 50-250 mg for each specimen, one specimen from tumor, another one from healthy breast tissue, the most distant from the cancer, were taken at the Department of Pathological Anatomy. The verification of the tissue being free from cancer cells was controlled histologically. The samples of breast tissue were put to weighted plastic tubes, once more weighted to find out a weight of the tissue sample and stored at -12°C until the analysis.
The patients were given oral instructions on how to obtain urine samples. After hygiene of perineum, about 10-30 ml of first morning urine had to be taken to a special plastic container. Plastic tubes with the samples of urine (5 ml) were stored at ?5°C until the analysis. About 2 ml of blood was taken from a patient to a special vacutainer at the time of admission to the Department of Surgery or prior to surgical treatment. The sample of blood (0.5 ml) diluted with some drops of de-ionized water, homogenized in 0.5 ml 0.125 M NaOH, and diluted to 5 ml with de-ionized water, mixed and stored at ?5°C until it was analyzed.
Analysis and quality assurance
The samples of breast tissue and blood were processed and mineralized in Multiwave 3000 (Anton Paar) by standard method [19] . Cd in biological media was determined by atomic absorption spectrometry (Perkin-Elmer, Zeeman 3030) [20] .
The accuracy and precision of the analytical procedures for breast tissue, urine, and blood Cd levels were assessed with a simultaneous analysis of a standard reference bovine liver (BCR 185R), urine (Seronorm , respectively. Certified values for Cd in the reference bovine liver, urine, and blood were 0.544 lg/g, 0.31 lg/l, and 0.74 lg/l dry-tissue weight, respectively. Our analysis of the reference bovine liver, urine, and blood gave means and standard deviation (SD) values (N = 14) of 0.53 ± 0.05 lg/g, 0.31 ± 0.03 lg/l, and 0.75 ± 0.07 lg/l dry-tissue weight for Cd, respectively. The coefficient of variation for Cd in bovine liver, urine, and blood was 9.43, 9.68, and 9.33%, respectively. Cd concentration in breast tissue was calculated as lg/g of wet weight.
Low sorption plastic tubes and labware used were repeatedly washed with 2.4 M nitric acid followed by repeated de-ionized pure water rinse to ensure they were free of contamination.
Measurements of hormone receptors and creatinine
The ER and progesterone-receptor (PR) levels were measured in the specimens of breast tissue from breast cancer patients by immunohistochemical method using markers of Novocastra [21] . In order to control kidney function [22] , creatinine in urine was determined by Jaffe method [23] .
Statistical analysis
Data analysis was processed using descriptive and comparative statistical methods which gave minimal and maximal values, median, mean, SD, and 95% confidence interval (CI). Since Cd concentrations in biological media were not distributed normally, non-parametric Spearman rank order correlation was used to assess statistical relationships between Cd and age (continuous variable) as well as smoking that was assessed by number of cigarettes smoked per life (continuous variable). According to ER status, cancer patients were divided into two groups: ER-positive group with ER?/PR-or ER?/PR? and ER-negative group with ER-/PR? or ER-/PR-. The Kruskal-Wallis and Wilcoxon non-parametric tests were used to compare indices among the groups. The level of significance was set at 5%. Data analysis was performed with the STATA 7 software program. Table 1 lists some characteristics of a study group. Breast cancer patients were almost twice older than controls, i.e., patients with benign breast tumor diagnose. Prevalence of smoking and number of cigarettes smoked per life did not differ between the groups compared.
Results
Of the cancer patients, 71.93% had carcinoma ductale, 8.77% carcinoma lobulare, 7.02% ductal carcinoma in situ, 12.28% other histological types of breast cancer. ER?/ PR?, ER?/PR-, ER-/PR?, and ER-/PR-were determined for 28.07, 19.3, 3.51, and 38.6% of cancer patients, respectively. Hormones receptors were not measured for patients with ductal carcinoma in situ or myoepithelial carcinoma (10.52%). Table 2 gives the mean and its 95% CI, minimal and maximal values and median for the levels of Cd determined in breast tissue, urine, and blood samples from breast cancer patients and controls with diagnosed benign breast tumor. Cancer patients had a 2.7-fold increase of breast tumor Cd concentration compared to their healthy breast tissue (P \ 0.001). Cd content in malignant tumor was 1.5 times greater than in benign tumor (P \ 0.01). Significant difference was found between the mean Cd value in breast tumor sample of cancer patients with ER? and ER- (Table 3) .
Cancer patients had a twofold increase of Cd content in urine adjusted for creatinine compared to controls (P \ 0.001) ( Table 2 ). No significant difference was found between the mean blood Cd level in cancer patients and controls (P [ 0.05). In cancer patients, Cd levels in tumor correlated significantly with Cd in healthy breast tissue and blood (Table 4) . Cd in healthy breast tissue correlated with Cd in blood. There was significant correlation between Cd in urine adjusted for creatinine and age. Correlations between Cd in urine and Cd in blood as well as smoking were suggestive (P = 0.075).
In controls Cd levels in tumor correlated significantly with Cd in healthy breast tissue, urine, blood, and age (0.339, 0.555, 0.414, and 0.490, respectively, P \ 0.05). Cd in healthy breast tissue correlated with Cd in urine and blood (0.298 and 0.293, P \ 0.05). There were significant correlations between Cd in urine adjusted for creatinine and age as well as smoking (0.774 and 0.536, P \ 0.05).
Cd concentration in urine of cancer patients from different groups in relation to smoking was greater than in controls from the corresponding groups (Table 5 ). Cancer patients both passive and active smokers had higher Cd in breast tumor tissue compare to controls. Cd in blood and healthy breast tissue did not differ significantly between the groups compared. There was no significant difference according to Cd found in both urine and breast tumor tissue of cancer patients smoking differentially and controls (P [ 0.05).
Discussion
Breast cancer remains the most common cause of cancer death among women in Europe with still rising number of deaths from the disease because of aging population (130,000 in 2004, 132,000 in 2006). In 2006, the agestandardized incidence rates of breast cancer were 26 and 25.8 per 100,000 women in Europe and Lithuania, respectively [24] . About half of breast cancer cases can be explained by known risk factors related to the reproductive life, inheritance, and socioeconomic status [25, 26] . The rest part of the cases could have an environmental etiology [27, 28] with Cd representing one of environmental risk factors.
In general population the primary sources of Cd are cigarette smoke, food, water, and ambient air particularly in urban areas and in the vicinity of industrial settings [29, 30] . About 10% of inhaled Cd is deposited in lung tissues and 30-40% is absorbed into blood [31] . Generally, Cd uptake in the gastrointestinal tract is 5-20% and depends on speciation of Cd, interactions between components in the diet affecting the bioavailability of Cd and the person's nutritional status. Approximately, 75% of the total dietary Cd intake is from vegetable food with the highest contribution from cereals [32, 33] . Owing to long half-life of Cd in the human body, it accumulates in the kidneys [34] . The urinary excretion of Cd is proportional to the body burden and used as a dose of lifetime exposure to Cd, whereas concentration in blood represents recent exposure [35] .
This study demonstrated greater Cd concentration in breast cancer than that in benign breast tumor tissue. These findings are in line with those reported by other authors [17, 18] . However, Antila et al. [16] did not find significant difference between breast-fat tissue Cd in cancer patients and healthy controls. We assume that the difference was not found because Cd was analyzed in the tissue as near to the malignant tissue as possible but not in malignant tissue. Inasmuch as, we made analysis of Cd in both breast tumor and healthy tissue samples, we found higher Cd content in malignant breast tumor than in benign tumor although there was no difference between Cd concentration in healthy breast tissue of cancer patients and that of controls. Even taking into account age difference between cancer patients and controls, the last finding supports an idea that the difference found between cadmium content in cancer and benign tumor is a real difference in cadmium level between the tumor types. We found that cancer patients with ER? had increased content of Cd in breast tumor compared to patients with ER-. These findings could be explained by some experimental studies reporting that Cd has an ability to form a high-affinity complex with the hormone-binding domain of the ER and therefore, functionally, acts like steroidal estrogens in breast cancer cells inducing their proliferation [8, 13] . Therefore, increased Cd level in breast cancer tissue and especially in breast cancer patients with ER? was very reliable.
Significant increase in urine Cd of cancer patients compared to controls obtained in our study was consistent with findings of epidemiological study [9] . We expected the difference to appear, because Cd concentration in urine demonstrated body burden of the metal and used as a dose of lifetime exposure to the metal [35] . Correlations between Cd in urine and age found in both cancer patients and controls were in line with previous statements. Significant difference in urine cadmium between cancer patients and controls remained after adjustment for age. Therefore, on the one hand, urine cadmium is related to age. On the other hand, women patients with breast cancer could have greater Cd content in urine and total body due to other reasons. One of them could be low body iron stores that increase Cd absorption [36] . There is also evidence for increased sensitivity to Cd toxicities in women [37] .
This study demonstrated significant correlation between Cd in urine and breast tissue (malignant and healthy) for controls. This relation was positive, but not statistically significant in cancer patients possibly due to rather small number of the patients.
Blood Cd levels in breast cancer patients did not differ significantly from that in benign breast tumor patients. Inasmuch as, blood Cd represents resent exposure to the metal [35] and breast cancer is a chronic disease, this finding could seem to be reliable on that matter. However, significant direct correlation between Cd in breast tissue (malignant and healthy) and blood either in cancer or in benign tumor patients is difficult to explain because (1) Cd in blood represents resent exposure; (2) Cd inclined to accumulate in the body and total body Cd correlates with Cd in urine; and (3) cancerogenesis is a long-term process. On the other hand, this correlation could be reliable because blood ''feeds'' whole organism and different tissues and cells continuously; hence, all metabolic processes are in close relationships. These statements are in line with suggestive correlation between Cd in urine and blood determined for cancer patients that could be ''strengthened'' further by a study on a large number of cancer patients.
Owing to low number of cigarette smoking women especially in cancer patients group (17.54%), we had some difficulties assessing association between Cd level in various biological media and smoking. Our data showed a suggestive relation (P = 0.075) between smoking and Table 5 Cadmium concentration in breast tissue (lg/g), urine (lg/l), and blood (lg/dl) according to smoking urine Cd in cancer patients; for controls, this relationship was significant. Even though urine Cd was higher in breast cancer patients from all groups in relation to smoking than that in corresponding groups of controls, its level differed neither between the cancer patients nor between the controls corresponding to different groups according to smoking. This could be due to greater exposure (active and passive) of smoking or another possible source of exposure to Cd such as a diet. We tried to estimate active and passive smoking quantitatively because, in previous analysis, smoking has been assessed only qualitatively taking into account answers ''yes'' or ''no.'' Although, exposure to smoking estimated quantitatively did not differ significantly between breast cancer patients and controls, it did not let us speculate on that matter, because such result could be due to low number of active and active/passive smokers within cancer patients and controls. A study in Finland defined that daily rate of smoking and number of smoking years had correlated positively with Cd concentration [16] . In that study, smoking was very common among breast cancer patients (43% of cases) as compared with general figures of smoking in Finnish women (20%).
Our cancer patients and controls differed significantly due to age because breast cancer is a disease mainly prevalent in older women [24] , whereas fibroadenoma is the most common benign breast tumor in adolescent girls and young women [38] . In spite of age difference found between the groups compared, we did not adjust Cd concentration in breast tissue for age, assuming that being a possible environmental-estrogen and accumulating in a human body it could simultaneously explain significance of age to the disease, especially knowing that breast cancer is a disease of postmenopausal women. Consequently, the adjustment for age would be underestimation of significance of Cd to breast cancer.
In conclusion, exposure to cadmium appears to be associated with breast cancer. Higher concentration of cadmium in breast cancer tissue and cancer patients' urine, assessing cumulative cadmium exposure from all sources including smoking and diet, supports a possible relationship between cadmium and breast cancer, although this conclusion is tempered by some methodological issues such as age difference between the groups compared and rather small number of the subjects. Whether cadmium is a cause of breast cancer may be answered by future studies that employ cadmium effect biomarkers, such as metallothioneins levels in breast tissue and blood, and take into account individual susceptibility to cadmium toxicity concerning metallothionein gene polymorphism.
